Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.64 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.52 |
| ▸ | CKS1B | P61024 | 2/20 | 0.51 |
| ▸ | SKP1 | P63208 | 2/20 | 0.51 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.51 |
| ▸ | TACR3 | P29371 | 7/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12279502 | 0.85 | TACR3 (0.59) | PDK2TACR3 | |
| SCHEMBL112363 | 0.85 | TACR3 (0.67) | P2RX7TACR3 | |
| SCHEMBL30980030 | 0.82 | P2RX7 (0.56) | PDK2P2RX7TACR3NR1H2MAPK1 | |
| SCHEMBL19005706 | 0.82 | RET (0.46) | PDK2NR1H2 | |
| SCHEMBL10095021 | 0.81 | NR1H2 (0.47) | PDK2P2RX7NR1H2MAPK1 | |
| SCHEMBL19005627 | 0.81 | P2RX7 (0.58) | PDK2P2RX7TACR3NR1H2 | |
| SCHEMBL30233019 | 0.81 | TACR3 (0.50) | PDK2P2RX7TACR3NR1H2 | |
| SCHEMBL24731072 | 0.81 | PDK2 (0.65) | PDK2CKS1BSKP1SKP2NR1H2 | |
| SCHEMBL1173978 | 0.81 | CKS1B (0.49) | PDK2CKS1BSKP1SKP2NR1H2 | |
| SCHEMBL22952373 | 0.80 | P2RX7 (0.48) | PDK2P2RX7NR1H2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018089433-A1 | PHENYL mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |